DB-1310 + osimertinib

DB-1310 + osimertinib is an experimental combination therapy consisting of DB-1310, a next-generation antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3), and osimertinib, a third-generation small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. DB-1310 delivers a cytotoxic DNA topoisomerase I inhibitor payload to HER3-expressing tumor cells[1][2]. Osimertinib irreversibly inhibits both sensitizing and T790M resistance mutations in the EGFR gene, primarily used for EGFR-mutated non-small cell lung cancer (NSCLC). The combination is under investigation for its potential synergistic antitumor activity, particularly in EGFR-mutant, HER3-expressing malignancies where resistance to previous EGFR tyrosine kinase inhibitor therapy has developed[1].